These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 19907417)

  • 21. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
    Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
    Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D
    Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
    Hermanowicz S; Hermanowicz N
    Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
    Pagan FL; Schulz PE; Torres-Yaghi Y; Pontone GM
    CNS Drugs; 2024 May; 38(5):333-347. PubMed ID: 38587586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
    Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
    Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial.
    Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S
    Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
    Abbas A; Roth BL
    Expert Opin Pharmacother; 2008 Dec; 9(18):3251-9. PubMed ID: 19040345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
    Ballard C; Youakim JM; Coate B; Stankovic S
    J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
    Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
    Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
    Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
    J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.